SUNPHARMA · Sun Pharmaceutical Industries Limited · BSE · Filed 7 Oct · 1 min read

Sun Pharma Board to Weigh NCD Issue of Up to ₹15,000 Crore on 12 October

The drugmaker will consider issuing listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis.

What was filed

Sun Pharmaceutical Industries said its board will meet on Monday, 12 October 2026 to consider and approve the issuance of listed, rated, unsecured, redeemable non-convertible debentures (NCDs). The intimation was made under Regulation 29 of SEBI's Listing Obligations and Disclosure Requirements Regulations, which requires prior notice of board meetings where such proposals are taken up.

Structure of the proposed issue

Per the filing, the NCDs would be issued in one or more tranches on a private placement basis, for an aggregate amount not exceeding the stated ceiling. The company described the instruments as listed, rated, unsecured and redeemable. No coupon, tenor, timing of tranches or intended use of proceeds was disclosed in this intimation.

What comes next

This is a pre-meeting intimation, not an approval. The actual terms — including whether the full ceiling is used — depend on what the board decides on 12 October and any subsequent disclosures. The filing commits only to the board taking up the proposal.

Maximum NCD issue size: INR 15,000 Crore

A debt raise of this potential scale could add to the company's borrowing profile; because the instruments are unsecured and privately placed, holders may watch the 12 October outcome and any follow-on disclosure for the final size, terms and purpose, none of which are specified here.